Quantcast
Last updated on April 23, 2014 at 11:40 EDT

Latest Antigen Express Inc. Stories

2014-03-26 12:28:30

WORCESTER, Mass. and TORONTO, March 26, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that Dr. Eric von Hofe, Ph.D., the President of its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a member of a panel discussing immunotherapies for solid tumors at the Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City...

2014-03-05 12:26:25

WORCESTER, Mass. and TORONTO, March 5, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) has received Notices of Allowance from the United States Patent Office relating to applications for the use of therapeutic vaccines targeting human papilloma virus (HPV) caused cancers as well as to potentially pandemic strains of influenza virus. The Company has...

2014-02-27 12:27:11

WORCESTER, Mass. and TORONTO, Feb. 27, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of studies examining potential biomarkers associated with overall survival in prostate cancer patients treated with its immunotherapeutic agent AE37. The retrospective study examined data from 29 patients immunized as part of a Phase I study. The immunotherapeutic agent AE37 is being developed by Antigen Express, Inc....

2014-02-12 12:30:03

WORCESTER, Mass. and TORONTO, Feb. 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011. The Company plans to disclose full results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO)...

2014-02-04 12:28:11

WORCESTER, Mass. and TORONTO, Feb. 4, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that an interview of Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), conducted by Stock News Now at last month's J.P. Morgan Healthcare Conference in San Francisco, is now available online. The interview is in respect of the ongoing Phase II trial of the Antigen Express...

2014-01-13 12:26:52

WORCESTER, Mass. and TORONTO, Jan. 13, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced completion of enrollment of the Antigen Express, Inc. (www.antigenexpress.com) AE37 breast cancer immunotherapy trial. The clinical trial is designed to assess the ability of AE37 to reduce the risk of relapse in patients who have had breast cancer. While a pre-planned primary efficacy analysis is underway, completion of enrollment sets the...

2014-01-09 12:26:12

Company Representatives will also attend the 32nd Annual J.P. Morgan Healthcare Conference next week in San Francisco WORCESTER, Mass. and TORONTO, Jan. 9, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a keynote speaker at IBC's 16(th) Annual TIDES Conference (www.IBCLifeSciences.com/Tides) to...

2014-01-06 08:27:53

WORCESTER, Mass. and TORONTO, Jan. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced the database lock for the primary efficacy analysis of its ongoing AE37 breast cancer vaccine trial. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). A previously released positive interim analysis showed a strong trend toward reduced...

2013-11-18 08:30:23

Primary Efficacy Analysis Initiated for Phase II Study of Novel Immunotherapeutic WORCESTER, Mass. and TORONTO, Nov. 18, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary,...

2013-08-20 08:31:01

WORCESTER, Mass. and TORONTO, Aug. 20, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of follow up studies from a Phase I clinical trial of its immunotherapeutic agent AE37 in patients with prostate cancer. The Phase I study demonstrated that the compound is safe, well-tolerated, and generated a specific and robust immune response. AE37 is being developed by the Company's wholly-owned subsidiary, Antigen Express Inc....